Phytochemical Found in Olive Oil Shows Promise Against Melanoma

Medical News: A New Hope in Cancer Research
A groundbreaking study has revealed that a compound found in extra virgin olive oil, known as ligstroside aglycone (LA), may hold potential in combating melanoma, a deadly form of skin cancer. Researchers from the University of Louisiana at Monroe-USA and Belmont University in Nashville-USA, conducted the study, focusing on the unique properties of LA and its effects on melanoma progression. This Medical News report dives into the key findings and what they could mean for future cancer therapies.


Phytochemical Found in Olive Oil Shows Promise Against Melanoma

Understanding Melanoma and the BRAF Mutation
Melanoma is a highly aggressive type of skin cancer, accounting for the majority of skin cancer-related deaths. In the United States alone, nearly 100,000 new cases are expected annually. A key player in melanoma progression is the BRAF gene, particularly its V600E mutation. This mutation causes continuous activation of the MAPK pathway, a critical signaling mechanism that drives tumor growth and survival. Current therapies targeting this mutation have shown promise but are often hindered by drug resistance and adverse side effects.
 
The researchers aimed to explore alternatives, particularly natural compounds, which led them to ligstroside aglycone - a rare secoiridoid derived from olive oil. This study highlights the potential of LA as a safer and more effective therapeutic option.
 
What is Ligstroside Aglycone?
Ligstroside aglycone is a monophenolic secoiridoid compound naturally found in extra virgin olive oil (EVOO). It belongs to a class of bioactive molecules derived from the cleavage of the cyclopentane ring in iridoids. Secoiridoids, particularly those found in EVOO, have long been associated with numerous health benefits, including anti-inflammatory, antioxidant, and anti-cancer properties. However, ligstroside aglycone has remained relatively understudied compared to other phenolic compounds like oleocanthal and hydroxytyrosol.
 
What makes ligstroside aglycone unique is its molecular structure, which allows it to interact with specific biological pathways involved in cancer progression. Unlike other EVOO phenolics, ligstroside aglycone is present in much smaller quantities, making its extraction and study more challenging. Recent advances in purification techniques have allowed scientists to isolate this compound with high purity, paving the way for research into its therapeutic potential. Ligstroside aglycone has demonstrated anti-inflammatory activity by modulating pathways like MAPKs, JAK/STAT, and NF-κB. Its ability to target multiple pathways positions it as a potent multitargeted agent against complex diseases like cancer.
 
In the context of melanoma, ligstroside aglycone’s ability to selectively inhibit the BRAF V600E mutation makes it particularly promising. This mutation drives unchecked cell growth in melanoma, and ligstroside aglycone’s specific targeting of this pathway provides a new mechanism for intervention. Its natural origin and safety profile further enhance its appeal as a therapeutic candidate.
 
How the Study Was Conducted
The study was carried out using both in vitro and in vivo models to assess LA’s anti-cancer properties. In the laboratory, LA was tested on a panel of 60 cancer cell lines, revealing its potent cytotoxic effects, especially against melanoma cells harboring the BRAF V600E mutation. Among the tested cell lines, Malme-3M showed the highest sensitivity to LA.
 
Researchers further examined LA’s effects using a mouse model. Tumor cells were introduced into mice, which were then treated with daily doses of LA. Results from this phase demonstrated significant tumor suppression without notable toxicity to the mice, suggesting a favorable safety profile. This study provides comprehensive insights into LA’s mechanisms of action.
 
Key Study Findings
-Inhibition of Tumor Growth
In the mouse model, tumors treated with LA showed a substantial reduction in size and weight compared to untreated tumors. On the final day of the study, the average tumor volume in the LA-treated group was 84.22 mm³, a dramatic decrease from the 382.4 mm³ observed in the control group. Tumor weights followed a similar trend, highlighting LA’s robust anti-tumor effects.
 
-Targeting the BRAF Signaling Pathway
LA’s most remarkable feature is its ability to specifically target the mutant BRAF V600E signaling pathway. This mutation leads to unchecked cell proliferation, but LA effectively disrupted this mechanism. Western blot analyses revealed that LA reduced the levels of key signaling proteins such as phosphorylated MEK and MAPK by 77.5% and 47.5%, respectively. Importantly, LA did not affect the wild-type BRAF protein, indicating its selectivity and reducing the likelihood of side effects.
 
-Inducing Focal Tumor Necrosis
Histological studies of tumor tissues showed extensive focal necrosis in the LA-treated group, a phenomenon absent in the control group. This suggests that LA induces localized tumor cell death, contributing to its anti-cancer effects.
 
-Modulating Gene Expression
Using advanced microarray analyses, researchers identified significant changes in gene expression in LA-treated tumors. Over 500 genes were dysregulated, including key players involved in cell adhesion, metabolic pathways, and immune responses. Notably, LA downregulated genes like GPD1 and ELOVL6, which are crucial for tumor cell metabolism and survival. These changes disrupt the tumor’s ability to grow and spread.
 
-Enhancing Immune Response
LA treatment also appeared to enhance the immune system’s ability to fight tumors. Markers associated with immune surveillance and response were upregulated, indicating that LA may help the body’s natural defenses target melanoma cells more effectively.
 
Broader Implications of the Findings
This study positions ligstroside aglycone as a promising candidate for melanoma treatment. Its ability to selectively target the BRAF V600E mutation, disrupt key metabolic pathways, and boost immune responses sets it apart from current therapies. Moreover, its natural origin and apparent safety profile offer significant advantages over synthetic drugs, which often come with severe side effects.
 
The implications extend beyond melanoma. The molecular mechanisms influenced by LA are shared by several other cancers, suggesting its potential utility in treating a broader range of malignancies. However, further research is necessary to validate these findings and explore practical applications.
 
Study Limitations and Future Directions
While the findings are promising, this research is still in its early stages. The study was conducted on animal models and cell lines, which may not fully replicate human biology. Clinical trials are essential to confirm LA’s efficacy and safety in humans. Additionally, researchers must investigate optimal dosing regimens and potential combinations with existing therapies to maximize benefits.
 
Conclusion
Ligstroside aglycone, a compound derived from olive oil, has emerged as a compelling candidate in the fight against melanoma. By targeting the BRAF V600E mutation and disrupting critical tumor pathways, LA demonstrates significant potential to overcome the challenges posed by current therapies. The study’s findings highlight a future where natural compounds play a central role in cancer treatment.
 
This study not only underscores the potential of ligstroside aglycone but also opens new avenues for exploring natural products in oncology. As researchers continue to delve into its mechanisms and applications, LA may one day become a cornerstone in melanoma therapy and beyond.
 
The study findings were published in the peer-reviewed journal: Molecules.
https://www.mdpi.com/1420-3049/30/1/139
 
For the latest on Herbs and Phytochemicals, keep on logging to Thailand Medical News.
 
Read Also:
https://www.thailandmedical.news/news/curcumin-and-thymoquinone-team-up-against-melanoma
 
https://www.thailandmedical.news/news/rising-incidence-of-thin-melanoma-in-norway-raises-alarm
 
https://www.thailandmedical.news/news/new-biomarker-for-melanoma-survival-and-treatment-unveiled-by-researchers
 
https://www.thailandmedical.news/news/thailand-led-medical-study-finds-that-malabar-spinach-shows-promise-in-preventing-skin-disorders-including-melanoma
 
https://www.thailandmedical.news/news/malignant-melanoma-a-new-hope-with-vitamin-d
 
https://www.thailandmedical.news/news/breaking-u-s-nih-and-brown-university-study-discovers-that-high-consumption-of-tuna-and-non-fried-fish-increases-risk-of-melanoma-cancer
 
https://www.thailandmedical.news/news/skin-cancer-new-immunotherapy-protocol-with-adoptive-t-cell-transfer-combined-with-dc-vaccination-shows-promise-for-advanced-skin-cancer
 
https://www.thailandmedical.news/news/new-combo-protocol-of-adoptive-cell-therapy-with-bempegaldesleukin-to-treat-advanced-melanoma
 
https://www.thailandmedical.news/news/malignant-melanoma-risk-lowered-after-bariatric-surgery-while-obesity-increases-its-risk
 
https://www.thailandmedical.news/news/researchers-discover-that-lactate-helps--melanoma-cells-to-spread
 
https://www.thailandmedical.news/news/anti-worm-drug,-flubendazole-can-be-repurposed--as-a-treatment-for-melanoma-cancer-pending-human-trials
 
https://www.thailandmedical.news/news/therapeutic-target-of-melanoma-discovered
 
https://www.thailandmedical.news/news/melanoma-in-the-brain-may-be-cured-by-immune-therapy